by nms-sync | Aug 3, 2022 | News
NMS Group S.p.A, an oncology R&D powerhouse with a biotech discovering and developing innovative therapies for the treatment of cancer, a CRO and CDMO that together push Oncology Forward, has announced the appointment of Andrew Curtis as Chief Strategy Officer...
by nms-sync | Aug 1, 2022 | News
Nerviano Medical Sciences S.r.l. (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today that it has expanded its presence in the US with the creation of a new US...
by nms-sync | Jul 19, 2022 | News
Nerviano Medical Sciences S.r.l., a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, recently announced that the first patient has been dosed in its Phase 1 clinical trial of NMS-812 in adult...
by nms-sync | Jun 29, 2022 | News
The Board of Directors of NMS Group S.p.A has approved today the company’s annual financial report, including the consolidated financial statements of the Group as of 31 December 2021.
“2021 was a challenging yet rewarding year for our Group. As we firmly believe...
by nms-sync | May 13, 2022 | News
Nerviano, 13 May 2022
MPS1, also known as monopolar spindle 1, is a protein kinase which is over-expressed and hyperactivated in different tumors and which plays a critical role in the control of mitosis (cell division) by regulating a process called the...
Welcome and Check out our new motion picture!
Recent Comments